NEWS
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
NeuroBo Pharmaceuticals revealed pre-clinical data for DA-1726, a new dual oxyntomodulin analog agonist, showing superior weight loss, lean body mass retention, and lipid-lowering effects compared to survodutide. In obese mouse models, DA-1726 significantly outperformed survodutide in reducing cholesterol (T-CHO: -67.7% vs. -49.6%) and triglycerides (TG: -49.5% vs. -41.2%). DA-1726 also demonstrated better glucose-lowering effects (-54.7% vs. -30.4% of survodutide). The drug's efficacy was tested at the ADA 84th Scientific Sessions in Orlando, June 21-24, 2024. The Phase 1 trial is ongoing, with initial dosing in Q3 and top-line data expected in Q1 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment